Strategy Asset Managers LLC Acquires New Stake in Moderna, Inc. $MRNA

Strategy Asset Managers LLC acquired a new position in shares of Moderna, Inc. (NASDAQ:MRNA) during the 3rd quarter, HoldingsChannel.com reports. The institutional investor acquired 13,021 shares of the company’s stock, valued at approximately $2,507,000.

Several other large investors also recently added to or reduced their stakes in MRNA. BlackRock Inc. purchased a new stake in shares of Moderna in the second quarter valued at $2,142,877,000. Theleme Partners LLP acquired a new stake in shares of Moderna in the second quarter worth $564,272,000. Merck & Co. Inc. acquired a new stake in shares of Moderna in the second quarter worth $161,642,545. Bamco Inc. NY acquired a new stake in shares of Moderna in the second quarter worth $139,317,000. Finally, Bank of New York Mellon Corp purchased a new position in shares of Moderna during the second quarter valued at $119,168,000. 75.33% of the stock is owned by institutional investors and hedge funds.

Moderna Stock Up 4.6%

Moderna stock opened at $226.30 on Thursday. The firm has a market cap of $90.35 billion, a PE ratio of -28.32 and a beta of 1.09. The company has a debt-to-equity ratio of 0.09, a quick ratio of 2.18 and a current ratio of 2.29. The firm’s 50 day moving average price is $149.83 and its two-hundred day moving average price is $88.67. Moderna, Inc. has a twelve month low of $22.28 and a twelve month high of $227.46.

Moderna (NASDAQ:MRNA) last released its earnings results on Friday, July 31st. The company reported ($1.97) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.03) by $0.06. The company had revenue of $145.00 million during the quarter, compared to the consensus estimate of $102.93 million. Moderna had a negative net margin of 141.43% and a negative return on equity of 28.30%. The company’s revenue was up 2.1% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($2.13) EPS. On average, research analysts predict that Moderna, Inc. will post -6.11 EPS for the current fiscal year.

Insider Activity

In other news, CFO James M. Mock sold 34,836 shares of the company’s stock in a transaction on Thursday, September 10th. The shares were sold at an average price of $134.49, for a total value of $4,685,093.64. Following the transaction, the chief financial officer directly owned 59,375 shares of the company’s stock, valued at approximately $7,985,343.75. This represents a 36.98% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Shannon Klinger sold 3,471 shares of the stock in a transaction on Tuesday, September 1st. The stock was sold at an average price of $139.95, for a total value of $485,766.45. Following the sale, the insider owned 74,129 shares of the company’s stock, valued at approximately $10,374,353.55. This represents a 4.47% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 118,882 shares of company stock worth $16,862,280 in the last ninety days. Corporate insiders own 10.80% of the company’s stock.

Trending Headlines about Moderna

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: Merck CEO Rob Davis said the companies expect their personalized cancer vaccine to become faster to manufacture as they refine the process. He described production as complex but said Merck and Moderna have reduced it to a highly controlled process, supporting expectations for improved scalability and broader commercial potential. Merck CEO tells CNBC he expects breakthrough cancer vaccine will become faster to make
• Positive Sentiment: Investor enthusiasm around Moderna’s positive cancer-vaccine results, along with its Nasdaq-100 inclusion, has driven a sharp weekly gain and expanded the company’s market capitalization. Moderna’s strength contrasts with weaker recent results from rival BioNTech, reinforcing its perceived leadership in mRNA oncology. MRNA Stock Gains Over $4B in a Week: Time to Buy, Hold or Sell?
• Neutral Sentiment: Moderna will report third-quarter 2026 results on November 6, providing a near-term catalyst. Investors will likely look for updates on revenue trends, cost controls, vaccine demand, clinical progress and the company’s path toward profitability. Moderna to Report Third Quarter 2026 Financial Results
• Negative Sentiment: The rapid rally has increased valuation risk. Investors are questioning whether Moderna’s future cancer-vaccine growth can justify the premium placed on the stock before commercial revenues and profitability are firmly established. MRNA Stock Gains Over $4B in a Week: Time to Buy, Hold or Sell?

Analyst Ratings Changes

Several research firms recently weighed in on MRNA. CLSA raised Moderna to an “outperform” rating in a research report on Friday, August 28th. Loop Capital set a $135.00 price objective on Moderna in a research note on Wednesday, August 19th. Bradesco Corretora raised Moderna to an “outperform” rating in a research note on Friday, August 28th. William Blair started coverage on Moderna in a research report on Friday, August 28th. They set an “outperform” rating for the company. Finally, Brookline Capital Markets reaffirmed a “buy” rating on shares of Moderna in a research note on Wednesday, August 19th. Seven investment analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and four have given a Sell rating to the company. According to data from MarketBeat, Moderna currently has an average rating of “Hold” and an average target price of $100.60.

Moderna Company Profile

Moderna, Inc is a biotechnology company that develops medicines and vaccines using messenger RNA (mRNA) technology. Its platform is designed to instruct cells to produce proteins that can help prevent or treat disease, supporting the company’s work across infectious diseases, immuno-oncology, rare diseases, autoimmune conditions, and cardiovascular diseases.

Moderna’s commercial products include Spikevax, an mRNA vaccine for COVID-19, and mRESVIA, an mRNA vaccine for respiratory syncytial virus (RSV) in older adults.